Pharmacokinetic Properties of 99mTc-PSMA: A New Radiopharmaceutical for SPECT Imaging of Prostate Cancer

Prostate-specific membrane antigen (PSMA), which is overexpressed in advanced prostate cancer, is a well-established target for the development of antitumor diagnostic and therapeutic radiopharmaceuticals. The aim of this work is the preclinical study of the pharmacokinetics of a new radiopharmaceut...

Full description

Saved in:

Bibliographic Details
Published in:	Physics of atomic nuclei Vol. 86; no. 11; pp. 2513 - 2518
Main Authors:	Tishchenko, V. K., Vlasova, O. P., Ivannikov, A. I., Dorovatovskiy, S. A., Pankratov, A. A., Morozova, N. B., Fedorova, A. V., Lebedeva, A. A., Kuzenkova, K. A., Stepchenkova, E. D., Khailov, A. M., Shegai, P. V., Ivanov, S. A., Kaprin, A. D.
Format:	Journal Article
Language:	English
Published:	Moscow Pleiades Publishing 01-12-2023 Springer Nature B.V
Subjects:	Kidneys Medical Physics and Biophysics Particle and Nuclear Physics Physics Physics and Astronomy Radiochemistry pharmacokinetics prostate cancer prostate-specific membrane antigen (PSMA) radionuclide diagnostics technetium-99m
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Prostate-specific membrane antigen (PSMA), which is overexpressed in advanced prostate cancer, is a well-established target for the development of antitumor diagnostic and therapeutic radiopharmaceuticals. The aim of this work is the preclinical study of the pharmacokinetics of a new radiopharmaceutical 99m Tc-PSMA. Tumor uptake of 99m Tc-PSMA is 1.81–3.91%/g with a maximum uptake of 3.91 ± 0.35%/g at 3 h of post-injection. The highest uptake (up to 140.11%/g) of 99m Tc-PSMA throughout the study was observed in the kidneys. Tumor uptake of 99m Tc-PSMA was higher than in other organs and tissues, except the kidneys
ISSN:	1063-7788 1562-692X
DOI:	10.1134/S1063778823110455